NFE2L2 and cardiomyopathy: These findings suggest that PRMT4 inhibits Nrf2/GPX4 signaling to exacerbate DOX-induced cardiac ferroptosis, targeting PRMT4 may help prevent the development and/or progression of DOX-induced cardiomyopathy.